What Fueled The Previous Growth In The Extavia Market?
The extavia market has seen considerable growth due to a variety of factors.
• In recent times, the market size for Extavia has shown an HCAGR of XX. The expected rise is from $XX million in 2024 to $XX million in 2025, with an anticipated compound annual growth rate (CAGR) of XX%.
The previous growth can be linked to factors such as insurance and reimbursement policies, preferred established treatments by physicians, a surge in healthcare spending, an increased occurrence of CNS disorders and minimal competition in the early years.
What Is The Expected Growth In The Extavia Market Size Evolve over the Forecast Period?
The extavia market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipations are that the extavia market will experience a XX (FCAGR) growth in the coming years, reaching a value of $XX million by 2029 due to a compound annual growth rate (CAGR) of XX%.
This predicted increase during the forecast period can be linked to the introduction of generic versions, the pivot towards oral MS treatments, state-mandated pricing guidelines, an aging demographic, and a rise in multiple sclerosis cases. Further contributions to advancement during the forecast period are expected from improvements in pharmaceutical development, focused therapies, funding in gene-altering technologies, the incorporation of AI in healthcare, and collaborations and partnerships.
What Main Forces Are Fueling Expansion In The Extavia Market?
The surge in the number of multiple sclerosis cases is projected to fuel the expansion of the extavia market. Multiple sclerosis (MS) is a chronic autoimmune condition that impacts the central nervous system (CNS), comprising the brain and spinal cord. The uptick in multiple sclerosis (MS) cases is attributed to several factors, such as enhanced diagnostic techniques, increased awareness, and potential shifts in environmental and lifestyle elements. Extavia is a drug that contains interferon beta-1b, employed in the treatment of relapsing-remitting multiple sclerosis (RRMS), by moderating the rate of relapses and decelerating disease progression through subcutaneous injections. For example, in January 2023, as per the SingleCare Administrators, a US-licensed discount medical plan organization, approximately 1 million individuals in the United States were affected by MS, while the estimated global figure was over 2.8 million. Consequently, the surge in multiple sclerosis cases is propelling the extavia market's growth.
What Are The Primary Segments In The Global Extavia Market?
The extavia market covered in this report is segmented –
1) By Clinical Indication: Relapsing-Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Other Multiple Sclerosis Forms
2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies
3) By Application: Subcutaneous Injection, Long-Term Disease Management, Prophylactic Use
Pre-Book The Extavia Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Extavia Market?
A significant trend observed in the Extavia market involves fine-tuning dosage instructions for Disease-Modifying Therapies (DMTs) among patients with Multiple Sclerosis (MS) to boost the efficacy of COVID-19 vaccines. This fine-tuning process changes the timing and method of administration of DMTs to optimize the protective effect of COVID-19 vaccinations, while still ensuring successful disease control in MS patients. For example, the National Multiple Sclerosis Society, an American nonprofit organization, has issued suggestions to enhance COVID-19 vaccine effectiveness among MS patients undergoing DMTs. As per these guidelines, treatments like Lemtrada and Mavenclad should be scheduled to have vaccinations administered four weeks prior to initiating treatment or 12 weeks post the last dose, with further modifications relative to individual schedules. For Extavia users, a commonly utilized DMT in MS patients, it is crucial to manage timing of the vaccinations diligently to achieve the desired benefits while maintaining stability in the treatment. Furthermore, MS patients on a regime of high dosage steroids are advised to schedule their first vaccine dose shortly after completion of their steroid treatment.
Who Are the Key Players In The Extavia Market?
Major companies operating in the extavia market include:
• Novartis AG
What Is The Most Dominant Region In The Extavia Market?
North America was the largest region in the extavia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extavia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
